Baird cuts Sarepta Therapeutics stock price target on growth concerns
Baird reduced its price target for Sarepta Therapeutics (SRPT) to $18.00 from $20.00, citing concerns over near-term growth of its Elevidys product. The company's Q3 revenue beat expectations but declined 20% year-over-year. SRPT reported adjusted earnings of $0.13 per share, exceeding estimates, but stock faced pressure due to weaker product sales and higher costs.
How this was made
The 30-second read
Why it matters
The target cut reflects concerns about enrollment lag and competitive headwinds, likely pressuring SRPT's share price.
Market read
Analyst downgrade may trigger short‑term sell‑off in SRPT and influence sentiment across biotech peers.
What to watch
Potential upside from upcoming MAD data in DM1 and FSHD later in 2026 could mitigate short‑term concerns.
Background
Baird's analysis follows SRPT's Q3 earnings, which showed a revenue beat but flat Elevidys sales and higher manufacturing costs.
Ticker impact
Baird lowered its price target on Sarepta Therapeutics to $18 from $20, citing near‑term growth concerns for Elevidys and a six‑month enrollment gap.
downward pressure as investors price in slower growth and lower target
Target reduction and neutral rating typically trigger short‑term sell‑side sentiment.
Market effects
May weigh on other gene‑therapy and biotech stocks as analysts scrutinize enrollment pipelines.
Limited to US biotech sector.
Low; impact confined to SRPT and peers.
Counterpoint
Some investors may view the price target cut as an overreaction given the recent revenue beat.
Key entities
- companySarepta Therapeutics
Biotech firm developing gene‑therapy treatments.
- analystBaird
Equity research firm issuing the price‑target revision.
